Shire and Santaris extend rare disease partnership

In Partnering & Investment by Tim Peplow

shire santaris rare disease partnership lna

Shire and Danish biopharma Santaris have agreed the renewal of a deal that sees the long-term partners working together to discover new drug targets for rare genetic diseases.

Santaris’ Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine can deliver drug candidates against RNA targets across a multitude of diseases. Under the terms of the extended agreement, Shire can nominate additional collaboration targets for drug discovery and development, and in turn Santaris will receive an undisclosed upfront payment alongside milestones and royalties.

The collaboration will work towards developing drugs to target rare diseases. “Our hope is that the partnership will eventually translate into novel drugs that will help patients suffering from debilitating rare diseases lead better lives,” said Albert Seymour, VP, Discovery Research at Shire.

Read the press release >

Join our discussion on LinkedIn, or leave a comment below. Want more from Total Orphan Drugs? Sign up to our newsletter – it doesn’t cost anything and only takes a minute.

The World Orphan Drug Congress Europe brings together pioneers from the orphan drug community, including key opinion leaders from the payer, HTA, public health and patient advocacy bodies. Download the brochure for the World Orphan Drug Congress Europe 2013, 14-15 November 2013, Geneva.